Comprehensive Diagnostic & Therapeutic Reference Profile
Also known as: Malignant melanoma, Cutaneous melanoma, Melanocytic carcinoma.
Melanoma is a malignant neoplasm originating from melanocytes, the pigment-producing cells of the epidermis. While less common than basal or squamous cell carcinomas, melanoma is the most lethal form of skin cancer due to its high propensity for early metastasis via the lymphatic and hematogenous routes.
Melanoma arises from the malignant transformation of melanocytes. Primary drivers include intermittent intense ultraviolet (UV) radiation exposure, genetic predisposition, and impairment of DNA repair mechanisms.
Melanoma involves the uncontrolled proliferation of melanocytes. Progression involves an initial "radial growth phase" (horizontal spread) followed by a "vertical growth phase" (invasion into the dermis), which correlates with metastatic potential. Common mutations include BRAF (V600E), NRAS, and c-KIT, leading to the constitutive activation of the MAPK/ERK signaling pathway.
It predominantly affects fair-skinned populations. Global incidence has risen significantly over the past decades. Peak incidence occurs between ages 50–60, though it is one of the most common cancers in young adults (ages 25–40).
A. Early Symptoms
Inspection reveals the ABCDE criteria: Asymmetry, Border irregularity, Color variation, Diameter >6mm, and Evolution. Palpation may reveal induration or associated lymphadenopathy.
A. Clinical Assessment: Dermoscopy.
B. Laboratory Testing: Serum LDH (marker for advanced disease).
C. Imaging Studies: PET/CT for staging.
D. Functional Tests: Not applicable.
E. Biopsy Findings: Excisional biopsy is the gold standard (Breslow depth assessment).
F. Genetic Testing: BRAF mutation analysis.
G. Differential Diagnosis: Seborrheic keratosis, pigmented basal cell carcinoma, atypical nevi.
Test Name: Lactate Dehydrogenase (LDH)
Type: Blood Test
Purpose: Staging/Prognosis
Expected Findings: Elevated levels
Interpretation: Suggests metastatic burden
Distinguished from benign seborrheic keratosis (lack of pigmentation features) and dysplastic nevi (by clinical stability and histopathology).
Metastasis to brain, lungs, liver, and bones; recurrence; psychological distress.
A. Lifestyle Modifications: UV protection.
B. Preventive Measures: Broad-spectrum sunscreen, protective clothing.
C. Medical Treatment: * Checkpoint inhibitors (Pembrolizumab, Nivolumab).
Prognosis is primarily dependent on Breslow thickness. Localized melanoma has a 5-year survival rate of ~99%, while metastatic disease survival drops to ~20–30%.
Avoidance of UV exposure, regular full-body skin examinations.
The following homeopathic remedies have been historically indicated for symptoms associated with Melanoma. Selection should be based on individualized symptom totality and constitutional assessment.
This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.
Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Melanoma.
Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, identify reference range variances, and generate a plain-English explanation of your disease risks.
Browse our full library of 200+ medical and pathology calculators.
📊 Browse All CalculatorsSpeak with our specialists for a customized treatment protocol for this condition.
📅 Request ConsultationThis clinical reference is for educational purposes only. It is not a substitute for professional medical diagnosis or treatment. Always consult a licensed healthcare practitioner.